Autopsy report · NCT04395378

Use of Dexcom G6 in Commercial Pilots With Insulin Treated Diabetes

“COVID-19 policy of the University of Surrey”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Suspended: paused, and may or may not restart.
• 30 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

University of Surrey

Sponsor type

University, hospital or other

Conditions

Type 1 Diabetes

Interventions

Continuous Glucose monitoring DEXCOM G6

Participants

30 (planned, not actual)

Sites

3

Countries

Austria, Ireland, United Kingdom

Trials that died the same way

• How Muscle and Tendon Properties Contribute to Functional Change Prior to and Following Knee Replacement
  “Due to COVID-19 and research restrictions put in place by the university” (74% match in meaning)
• High Risk Outpatient Intern-led Care (HeROIC) Clinic Initiative
  “Covid-19, funding” (65% match in meaning)
• RESIST-2: 2nd-line ART for HIV-2 Infection
  “COVID-19 and Funding” (65% match in meaning)
• Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
  “COVID-19 Research Restrictions” (64% match in meaning)
• Evaluation of Surgery in Elderly With Traumatic Acute SubDural Hematoma
  “Lack of inclusion / COVID-19 regulations” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.